Dose-response experiments are a mainstay of receptor biology studies and can reveal valuable 13 insights into receptor function. Such studies of receptors that bind cell surface ligands are 14 currently limited by the difficulty in manipulating the surface density of ligands at a cell-cell 15 interface. Here we describe a generic cell surface ligand system that allows precise 16 manipulation of cell surface ligand densities over several orders of magnitude. We validate the 17 system for a range of immunoreceptors, including the T cell receptor (TCR), and show that this 18 generic ligand stimulates via the TCR at a similar surface density as its native ligand. This 19 system allows the effect of surface density, valency, dimensions, and affinity of the ligand to be 20 manipulated. It can be readily extended to other receptor-cell surface ligand interactions, and 21 will facilitate investigation into the activation of, and signal integration between, cell surface 22 receptors. 23 1 24 Many cellular receptors are activated by ligands presented on other cell surfaces. To study 25 these receptors in depth, cell lines expressing the appropriate physiological ligand are required. 26 Conducting dose-response experiments on these receptors is challenging as controlling ligand 27 density on the surface of cells is difficult. Currently this is limited to sorting cells into populations 28 with varying expression levels, using inducible expression systems, or the use of blocking 29 antibodies. An alternative to physiological ligands that is commonly used is antibodies specific 30 for a receptor or recombinant ligands presented on artificial surfaces, such as plastic or 31 glass-supported lipid bilayers. However, this can be a poor mimic for the complexity and 32 biophysical characteristics of cell surfaces. 33 One widely studied group of receptors are non-catalytic tyrosine-phosphorylated receptors 34 (NTRs), also called immunoreceptors, which are the largest group of receptors expressed on 35 leukocytes 1 . These receptors play a major role in the recognition of infected or cancer cells. 36 Since some NTRs, such as the T cell receptor (TCR), cytotoxic T-lymphocyte-associated 37 antigen-4 (CTLA-4) and programmed death-1 (PD-1), have been successfully 38 manipulated/targeted for therapeutic purposes 2,3 , the remaining NTRs are currently under 39 intense investigation for the development of immunotherapies (examples include 4-7 ). 40 The mechanism of signal transduction, or triggering, has been studied in depth for some NTRs 41 (notably the TCR) but remains controversial 1,8 . Due to the widespread importance of NTR 42 function in immune regulation, and huge interest in their activity, elucidating this mechanism is 43 critical to both our understanding and ability to modulate receptor activity where required in 44 clinical settings. While NTRs have conserved signalling modules, their extracellular regions are 45 rapidly evolving, hugely diverse, and bind a structurally-diverse range of ligands 1 . This diversity, 46 and the fact that their ligands are often not known, has hampered a systematic investigation of 47 NTRs. 48 These limitations motivated us to develop new tools for investigating receptors that have cell 49 surface ligands. We present a novel generic ligand system whereby a single ligand can engage 50 any receptor engineered to have an accessible tag. We show that ligand density can be varied 51 easily and precisely quantified and we show that the generic ligand can activate a number of 52 2 representative NTRs in a clear dose-dependent manner. For one receptor, the TCR, we 53 compare the response to generic versus physiological ligand: peptide presented in major 54 histocompatibility complexes (pMHC). 55 Finally, we describe and briefly show how this generic ligand can be manipulated to alter other 56 biochemical and biophysical properties of receptor-ligand interactions such as dimensions, 57 affinity and valency. These modifications to a single ligand will apply to any interaction involving 58 the ligand and a tagged receptor and thus permit high-throughput, systematic analyses of 59 multiple receptors. 60 3
Introduction Preparation of trivalent Strep-Tactin-SpyCatcher
A time course showed that a significant proportion of generic ligand remains at the cell surface 141 for many hours post-reconstitution ( Supplementary Fig. 2 ). Receptor stimulation assays are 142 commonly conducted over this time frame so the ligand is able to provide a strong stimulus for 143 this duration. 144 Measuring the number of generic ligands per cell 145 A major strength of the generic ligand system is the ligand dose can be varied easily by titrating 146 the concentration of soluble trivalent Strep-Tactin-SpyCatcher added to cells. To enable us to 147 determine the ligand surface density required for activation we developed a method to measure 148 the number of generic ligands per cell. This method uses two assays. The first, whereby CHO 149 generic ligand cells are incubated with ATTO 647 biotin, gives an indication of how the relative 150 number of generic ligand sites varies with Strep-Tactin-SpyCatcher concentration (Fig. 2b) . 151 The second assay measures the average maximum number of generic ligands per cell in a 152 population of cells saturated with trivalent Strep-Tactin-SpyCatcher. This uses the same 153 biotin-4-fluorescein fluorescence quenching assay shown in Supplementary Fig. 1 . Assuming 154 complete binding, the biotin-4-fluorescein concentration that saturates the cells is indicated by 155 the inflection point of the graph (Fig. 2c ). This saturating concentration for a known number of 156 cells in a defined volume can then be converted into an average number of generic ligands per Signal regulatory protein βI (SIRPβI, CD172b) and Siglec-14 are expressed in a number of leukocytes including monocytes and macrophages 23, 24 . Siglec-14 binds to sialic acid presented 168 by numerous bacteria to induce responses including cytokine secretion 24 . There is evidence 169 that SIRPβI contributes to neutrophil transepithelial migration and macrophage phagocytosis, 170 but a ligand has yet to be identified 23 . A generic ligand is therefore very useful for the study of 171 SIRPβI. As a member of the natural killer cell cytotoxicity family, NKp30 (CD337) is expressed in 172 natural killer (NK) cells and binds both pathogen and cellular ligands to mediate NK cell 173 cytotoxicity 25 . 174 SIRPβI, Siglec-14, and NKp30 receptors each associate with adaptor proteins that contain 175 cytoplasmic phosphorylatable tyrosine residues that mediate immune signalling [23] [24] [25] . Therefore, 176 to establish stable cell lines, THP-1 cells were co-transduced with lentiviruses encoding the 177 tagged receptor and appropriate adaptor ( Supplementary Fig. 3 ). 178 The αβT cell receptor (TCR) complex consists of TCR α and β chains associated with a TCRζ Supplementary Fig. 3 ) 26, 27 . Any IG4 TCR α and β chains expressed at the cell surface are 184 presumed to be associated with endogenous TCR/CD3 signalling subunits. 185 All four tagged receptors were activated by generic ligand cells with a clear dose-dependent 186 response which increased with the number of generic ligands per cell ( Fig. 3b-e ). This response 187 was specific as shown by the absence of IL-8 secretion or NFκB-driven eGFP expression in 188 samples containing negative control receptor cells ( Fig. 3b-e ) or ligand cells (data not shown). 189 The EC 50 and hill slope values of the receptor responses from three independent experiments 190 are shown in Table 1 . Thus the generic ligand can bind to and trigger several different receptors 191 bearing an N-terminal Twin-Strep-tag. Twin-Strep-tagged T cell receptor responds to generic ligand and native ligand with a similar sensitivity 194 In order to validate this approach we compared the response of the TCR to generic ligand with 195 its response to native ligand, peptide-MHC. 196 IG4 TCR and its cognate ligand NY-ESO-1 157-165 9V peptide variant (SLLMWITQV) presented 197 in complex with HLA-A*02 is a well characterised receptor-ligand pair [28] [29] [30] . The dissociation 198 constant of IG4 TCR binding to 9V-HLA-A*02 (K D = 6-7 µM) is comparable to the K D we have 199 measured for Twin-Strep-tag and trivalent Strep-Tactin-SpyCatcher ( Fig. 2a) 29, 30 . 200 To compare the TCR response to either generic or native ligand, the Jurkat NFκB reporter cell 201 line transduced with IG4 TCR α and Twin-Strep-tagged β chains ( Supplementary Fig. 3 ) was 202 presented to CHO cells that express both HLA-A*02 in the form of a single chain dimer and the 203 generic ligand anchor ( Fig. 4a, Supplementary Fig. 3 ). These CHO cells were either 204 pre-incubated with trivalent Strep-Tactin-SpyCatcher or loaded with 9V peptide. To allow a direct 205 comparison between generic and pMHC ligand the Jurkat cells were not transduced with the 206 co-receptor CD8, since it binds MHC but not generic ligand. 207 In order to quantitatively compare the TCR response to generic ligand or 9V-HLA-A*02, we 208 measured the number of 9V-HLA-A*02 molecules on the CHO ligand cells. For this, we used a 209 soluble affinity-enhanced (c58/c61) form of the IG4 TCR that binds to 9V-HLA-A*02 with a much 210 higher affinity than the wild-type TCR (K D = 71 pM) 31,32 . This soluble IG4 high affinity TCR was 211 labelled with Alexa Fluor 647 (IG4hi TCR AF647) and used in combination with fluorescence 212 quantitation beads to interpolate the average number of 9V-HLA-A*02 per cell (Fig. 4b , 213 Supplementary Fig. 4 ). Incubating CHO ligand anchor HLA-A*02 cells with varying 214 concentrations of 9V peptide yielded a large dynamic range of ligand number per cell (Fig. 4b) . 215 Therefore, we were able to present Jurkat IG4 TCRα/β-Twin-Strep-tag cells with CHO ligand 216 anchor HLA-A*02 cells presenting either 9V-HLA-A*02 or generic ligand at similar 217 densities. 218 Jurkat IG4 TCRα/β-Twin-Strep-tag cells responded to both 9V-HLA-A*02 and generic ligand in a 219 dose-dependent, specific manner, visualised using the NFκB reporter (Fig. 4c ). The EC 50 and 220 9 hill slope values from three independent experiments are shown in Table 1 . There is a 2-fold 221 difference in the average sensitivity between the receptor response to 9V-HLA-A*02 versus 222 generic ligand. We believe the variability of 9V-HLA-A*02 EC 50 values arises from 223 inter-experiment variability in estimating the number of 9V-HLA-A*02 molecules per cell. 224 Based on the structure of soluble IG4 TCRα/β bound to cognate pMHC we predict the presence 225 of Twin-Strep-tag should not interfere with TCR-pMHC binding (PDB accession number: 226 2BNR) 29 . We used soluble pMHC class I tetramer staining to confirm this. Because tetramer 227 staining of Jurkat IG4 TCRα/β cells in the absence of CD8 co-receptor expression was very 228 poor (data not shown) we used cells that express CD8. Jurkat cells expressing either 229 non-tagged, Strep-tag II-tagged or Twin-Strep-tagged IG4 TCRα/β, and CD8α/β, were matched 230 for TCRβ chain and CD8α expression ( Supplementary Fig. 4 ). These cells showed comparable 231 cognate pMHC tetramer staining ( Supplementary Fig. 4 ) suggesting the presence of Strep-tag II 232 does not significantly interfere with pMHC binding. 233 In summary, we have demonstrated that the generic ligand can elicit a receptor response 234 comparable to physiological ligand, reinforcing its usefulness for studying receptor 235 activation. 236 Manipulating the generic ligand system 237 Our generic ligand system could be adapted to allow manipulation of ligand properties other 238 than surface density, such as length, affinity, and valency, as illustrated in Fig expressed with its adaptor in THP-1 cells was able to respond to monovalent 247 Strep-Tactin-SpyCatcher∆ presented on CHO cells ( Fig. 5d ). As we would predict, the EC 50 of 248 10 this response to a lower affinity interaction was higher, by approximately six-fold, compared to 249 that measured for Siglec-14 with Twin-Strep-tag and trivalent Strep-Tactin-SpyCatcher (mean 250 EC 50 values of 1,100,000 and 190,000 generic ligands per cell respectively). 251 
Discussion

252
We describe a novel generic ligand system that facilitates the investigation of receptors that bind 253 cell surface ligands. This ligand is stably presented on the surface of CHO cells, and the ligand 254 density can be easily titrated over several orders of magnitude. We believe this fine control over 255 ligand dose within a cell environment is a clear advantage over current methods with 256 physiological ligand. 257 We show that four representative NTRs can be stimulated by ligation of N-terminal 258 Twin-Strep-tag. These results show that specific engagement of native ligand is not required for 259 receptor triggering. This is in agreement with other work that shows these NTRs, among others, experiments were 130,000-260,000 ligands per cell (Table 1 ). In contrast, the IG4 TCR 265 responds with a much lower mean EC 50 of 17,000 ligands per cell, indicating that TCR triggering 266 required much lower surface densities of generic ligand than other NTRs (Table 1) . 267 Furthermore, the ligand densities of our generic ligand required to elicit responses were 268 comparable to the required ligand densities of native ligands reported by others [33] [34] [35] [36] [37] . 269 A number of manipulations can be made to the generic ligand system to investigate the basic 270 requirements and optimal conditions for NTR activation, as outlined in Fig. 5a -c. Increasing the 271 extracellular dimensions of the generic ligand by inserting inert spacer domains into the anchor 272 would enable testing whether ligand length affects recognition, as predicted by the 273 kinetic-segregation model of NTR triggering ( Fig. 5a) 1, 38 . Until now these experiments have 274 been painstaking as they require expressing different length forms of each native ligand at 275 11 matched levels, and titration of ligand density is not possible 1, 39 . 276 We also illustrate how the receptor-generic ligand affinity can be altered through using 277 alternative SpyCatcher fusion proteins and/or variants of the Strep-tag II/Twin-Strep-tag system 278 ( Fig. 5b,d , Supplementary Fig. 5-6 ). Thus the sensitivity of receptors to affinity changes, and 279 whether there is an optimal ligand binding affinity for various NTRs, can be explored in a 280 high-throughput manner. 281 The K D values we measured for Twin-Strep-tag-mTFP binding to trivalent Fig. 5d ). 289 The role of receptor clustering in receptor triggering can also be explored by varying the valency 290 of the generic ligand ( Fig. 5c ). This can be achieved by refolding Strep-Tag II binding and 291 non-binding (dead) Strep-Tactin subunits in varying ratios. Large-scale receptor clustering could 292 also be induced using larger multivalent ligand complexes 40 . 293 The high density of generic ligand that can be achieved provides an opportunity to use more 294 than one soluble SpyCatcher fusion protein to provide combinations of more than one ligand. 295 For example, a "second generic ligand" could engage co-stimulatory and/or co-inhibitory NTRs 296 or other immune receptors. Such an approach greatly extends our ability to explore not just 297 receptor activation but also signal integration between multiple receptors. 298 Recently a split receptor system has been described based on expression of a universal cell 299 surface signalling component to which soluble antigen receptors of diverse specificities can be 300 coupled 7 . While such a system is useful for flexible, programmable targeting of effector cells, 301 because the surface density of ligands cannot be precisely varied it is less helpful for studying 302 the mechanisms of immune recognition and receptor triggering. 303 The generic ligand system, and future work building upon foundations laid here, will aid 304 12 investigations into the processes that regulate immune signalling and signal integration. In 305 principle, it can also be adapted to analyse the vast array of other receptor-cell surface ligand 306 interactions that exist in a systematic, high-throughput manner. 307 
Materials and Methods
308
All data were fitted using GraphPad Prism or FlowJo software. In all cases where sample values 309 were below the machine detection limit, those samples were given a value of 0. terminus of the TCRβ chain. IG4 TCR was amplified without the native β chain signal peptide. 329 The α and β chains also have a C-terminal FLAG tag and HA tag respectively. 
For Jurkat cell assays, only CD45+ cells were analysed for eGFP. Negative control populations 635 were used to set a gate on eGFP expression (see Supplementary Fig. 7) . The percentages of 636 CD45+ cells positive for eGFP were extracted and corrected for corresponding background % 
